jj agrees 25bn guidant deal pharmaceutical giant johnson johnson agree buy medical technology firm guidant 254bn 13bn guidant key producer equipment combat heart problem implant defibrillator pacemaker analyst say deal aim offset johnson johnson reliance slow drug business also point merger likely drug healthcare industry fragment pressure cut cost number johnson johnson product face patent expiration company also battling fierce competition generic product meanwhile demand defibrillator give heart small electric shock irregular heartbeat rhythm detect expect increase analyst say move johnson johnson widely expect firm will pay 76 guidant share 6 wednesday closing price analyst say us antitrust regulator force firm overlap stent operation stent tube use keep artery open unblocked 